K
Klaus Baumann
Researcher at University of Marburg
Publications - 56
Citations - 3759
Klaus Baumann is an academic researcher from University of Marburg. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 22, co-authored 44 publications receiving 2770 citations. Previous affiliations of Klaus Baumann include University Hospital of Giessen and Marburg & Ohio State University.
Papers
More filters
Journal ArticleDOI
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Antonio González-Martín,Bhavana Pothuri,Ignace Vergote,René dePont Christensen,Whitney Graybill,Mansoor Raza Mirza,C McCormick,Domenica Lorusso,Paul Hoskins,Gilles Freyer,Klaus Baumann,K. Jardon,Andrés Redondo,Richard G. Moore,Christof Vulsteke,Roisin E. O'Cearbhaill,Bente Lund,Floor J. Backes,Pilar Barretina-Ginesta,Ashley Haggerty,Maria J. Rubio-Pérez,Mark S. Shahin,Giorgia Mangili,William H. Bradley,Ilan Bruchim,Kaiming Sun,I Malinowska,Y. Li,Divya Gupta,Bradley J. Monk,Engot-Ov,Gog Investigators +31 more
TL;DR: Among patients with newly diagnosed advanced ovarian cancer who had a response to platinum-based chemotherapy, those who received niraparib had significantly longer progression-free survival thanThose who received placebo, regardless of the presence or absence of homologous-recombination deficiency.
Journal ArticleDOI
Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
Gunter von Minckwitz,Andreas du Bois,Marcus Schmidt,Nicolai Maass,Tanja Cufer,Felix E. de Jongh,E. Maartense,Christoph C. Zielinski,Manfred Kaufmann,Wolfgang R. Bauer,Klaus Baumann,Michael R. Clemens,Ralph Duerr,Christoph Uleer,Martin Andersson,Robert Stein,Valentina Nekljudova,Sibylle Loibl +17 more
TL;DR: Continuation of trastuzumab beyond progression was not associated with increased toxicity and showed a significant improvement in overall response and time to progression compared with capecitabine alone in women with HER-2-positive breast cancer who experienced progression during trastzumab treatment.
Journal ArticleDOI
Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer
Andreas du Bois,Anne Floquet,Jae Weon Kim,Jae Weon Kim,Joern Rau,Josep M. del Campo,Michael Friedlander,Sandro Pignata,Keiichi Fujiwara,Keiichi Fujiwara,Ignace Vergote,Nicoletta Colombo,Mansoor Raza Mirza,Bradley J. Monk,Rainer Kimmig,Isabelle Ray-Coquard,Rongyu Zang,Ivan Diaz-Padilla,Klaus Baumann,Marie Ange Mouret-Reynier,Jae Hoon Kim,Jae Hoon Kim,Christian Kurzeder,Christian Kurzeder,A. Lesoin,Paul Vasey,Christian Marth,Ulrich Canzler,Ulrich Canzler,Ulrich Canzler,Giovanni Scambia,Muneaki Shimada,Muneaki Shimada,Paula Calvert,Eric Pujade-Lauraine,Byoung Gie Kim,Thomas J. Herzog,Ionel Mitrica,Carmen Schade-Brittinger,Qiong Wang,Rocco Crescenzo,Philipp Harter +41 more
TL;DR: Pazopanib maintenance therapy provided a median improvement of 5.6 months in progression-free survival in patients with advanced ovarian cancer who have not progressed after first-line chemotherapy, and additional analysis should help to identify subgroups of patients in whom improved efficacy may balance toxicity.
Journal ArticleDOI
Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group.
Andreas du Bois,N. Ewald-Riegler,Nikolaus de Gregorio,Alexander Reuss,Sven Mahner,Christina Fotopoulou,Friedrich Kommoss,B Schmalfeldt,Felix Hilpert,Tanja Fehm,Alexander Burges,Werner Meier,Peter Hillemanns,Lars Hanker,Annette Hasenburg,Hans-Georg Strauss,Martin Hellriegel,Pauline Wimberger,Mignon-Denise Keyver-Paik,Klaus Baumann,Ulrich Canzler,K. Wollschlaeger,Dirk Forner,Jacobus Pfisterer,W. Schröder,K. Münstedt,Barbara Richter,Stefan Kommoss,Steffen Hauptmann +28 more
TL;DR: A retrospective-prospective cohort study on borderline ovarian tumours to better understand BOT and identify scenarios in which future studies could be developed revealed higher stage, incomplete staging, tumour residuals, and organ preservation as independent prognostic factors for disease recurrence.
Journal ArticleDOI
Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer.
Gunter von Minckwitz,K. Schwedler,Marcus Schmidt,Jana Barinoff,Christoph Mundhenke,Tanja Cufer,E. Maartense,Felix E. de Jongh,Klaus Baumann,Joachim Bischoff,Nadia Harbeck,Hans-Joachim Lück,Nicolai Maass,Christoph C. Zielinski,Martin Andersson,Robert Stein,Valentina Nekljudova,Sibylle Loibl +17 more
TL;DR: Final overall survival analysis of the GBG-26 study did not demonstrate a significant survival benefit for treatment beyond progression with trastuzumab, however, in a post-hoc analysis, patients receiving anti-HER2 treatment as 3rd line therapy showed a better post-progression survival than those not receiving this targeted treatment.